No Cover Image

Journal article 104 views 15 downloads

Finerenone in the management of diabetes kidney disease

Parijat De, May T Khine, Andrew Frankel, Gabrielle Goldet, Debasish Banerjee, Rosa M Montero, Tahseen A Chowdhury, Damien Fogarty, Janaka Karalliedde, Ritwika Mallik, Dipesh C Patel, Mona Wahba, Peter Winocour, Sagen Zac-Varghese, Steve Bain Orcid Logo, Adnan Sharif, Srikanth Bellary, Indranil Dasgupta

BMC Nephrology, Volume: 26, Issue: 1

Swansea University Author: Steve Bain Orcid Logo

  • 68787.VoR.pdf

    PDF | Version of Record

    © The Author(s) 2025. This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

    Download (1003.66KB)

Check full text

DOI (Published version): 10.1186/s12882-025-03985-9

Abstract

People with type 2 diabetes are at risk of developing progressive diabetic kidney disease (DKD) and end stage kidney failure. Hypertension is a major, reversible risk factor in people with diabetes for development of albuminuria, impaired kidney function, end-stage kidney disease and cardiovascular...

Full description

Published in: BMC Nephrology
ISSN: 1471-2369
Published: Springer Science and Business Media LLC 2025
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa68787
Abstract: People with type 2 diabetes are at risk of developing progressive diabetic kidney disease (DKD) and end stage kidney failure. Hypertension is a major, reversible risk factor in people with diabetes for development of albuminuria, impaired kidney function, end-stage kidney disease and cardiovascular disease. Slowing progression of kidney disease and reducing cardiovascular events can be achieved by a number of means including the targeting of blood pressure and the use of specific classes of drugs The use of Renin Angiotensin Aldosterone System (RAAS) blockade is effective in preventing or slowing progression of DKD and reducing cardiovascular events in people with type 2 diabetes, albeit differently according to the stage of DKD. However, emerging therapy such as non-steroidal selective mineralocorticoid antagonists (finerenone) is proven to lower blood pressure and further reduce the risk of progression of DKD and cardiovascular disease in people with type 2 diabetes. This consensus reviews current evidence and make recommendations for the use of finerenone in the management of diabetes kidney disease in the UK.
Keywords: Diabetes; Hypertension; Albuminuria; Diabetic kidney disease; Finerenone; ACE inhibitors; Angiotensin receptor blockers; Renin Angiotensin Aldosterone System (RAAS)
College: Faculty of Medicine, Health and Life Sciences
Issue: 1

Similar Items